{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:23Z","timestamp":1780920623166,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":117,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101233","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:21:47Z","timestamp":1777602107000},"page":"101233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review"],"prefix":"10.1016","volume":"47","author":[{"given":"Victoria L.","family":"Cammann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menzi","family":"Sheryl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-1818","authenticated-orcid":false,"given":"Andreas W.","family":"Jehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101233_bib0001","first-page":"2275","article-title":"Euvolemic hyponatremia in cancer patients. report of the hyponatremia registry: an observational multicenter international study","volume":"25","author":"Burst","year":"2017","journal-title":"Supp. Care Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.21037\/tcr.2019.12.72","article-title":"Hyponatremia and hypercalcemia: a study of a large cohort of patients with lung cancer","volume":"9","author":"Chan","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101233_bib0003","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jama.2022.11176","article-title":"Diagnosis and management of hyponatremia: a review","volume":"328","author":"Adrogue","year":"2022","journal-title":"JAMa"},{"key":"10.1016\/j.ctarc.2026.101233_bib0004","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2026.101233_bib0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00063198-200307000-00012","article-title":"Endocrine paraneoplastic syndromes in lung cancer","volume":"9","author":"Mazzone","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0006","doi-asserted-by":"crossref","first-page":"359","DOI":"10.21037\/atm.2019.04.86","article-title":"Paraneoplastic syndromes in lung cancer and their management","volume":"7","author":"Anwar","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2265.2006.02583.x","article-title":"Characteristics and mortality of severe hyponatraemia\u2013a hospital-based study","volume":"65","author":"Gill","year":"2006","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2466-13-55","article-title":"A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan","volume":"13","author":"Petereit","year":"2013","journal-title":"BMC. Pulm. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0009","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1681\/ASN.0000000588","article-title":"Syndrome of inappropriate antidiuresis","volume":"36","author":"Rosner","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/11204630-000000000-00000","article-title":"Tolvaptan","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ctarc.2026.101233_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0012","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0013","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Efficacy of Vasopressin antagonism in heart failure outcome study with Tolvaptan, effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMa"},{"key":"10.1016\/j.ctarc.2026.101233_bib0014","article-title":"Interventions for preventing the progression of autosomal dominant polycystic kidney disease","volume":"10","author":"St Pierre","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ctarc.2026.101233_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00134-014-3210-2","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"40","author":"Spasovski","year":"2014","journal-title":"Intens. Care Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0018","doi-asserted-by":"crossref","DOI":"10.5301\/tj.5000249","article-title":"Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH","volume":"101","author":"Bordi","year":"2015","journal-title":"Tumori."},{"key":"10.1016\/j.ctarc.2026.101233_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1382066","article-title":"Case report: secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH","volume":"15","author":"Menzi","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s13730-019-00375-7","article-title":"Tolvaptan corrects hyponatremia and relieves the burden of fluid\/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases","volume":"8","author":"Kai","year":"2019","journal-title":"CEN. Case Rep."},{"key":"10.1016\/j.ctarc.2026.101233_bib0021","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00228-017-2363-7","article-title":"Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer","volume":"74","author":"Garrahy","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(14)70187-4","article-title":"186 Use of tolvaptan, a new V2 receptor antagonist, in the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH) secondary to small cell lung cancer (SCLC) \u2013 a case series","volume":"83","author":"Fraser","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(12)70182-4","article-title":"181 Tolvaptan use in a patient with metastatic small cell lung cancer","volume":"75","author":"Mumby","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0024","first-page":"612","article-title":"Tolvaptan resistance in severe SIADH","volume":"30","author":"Segal","year":"2019","journal-title":"J. America. Soc. Nephrol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0025","article-title":"SIADH escape or Tolvaptan resistance in progressive small cell lung cancer: SA-PO470","volume":"33","author":"Mandal","year":"2022","journal-title":"J. America. Soc. Nephrol."},{"key":"10.1016\/j.ctarc.2026.101233_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fmed.2017.00141","article-title":"Vasopressin receptor antagonists in hyponatremia: uses and misuses","volume":"4","author":"Rondon-Berrios","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0027","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0028","doi-asserted-by":"crossref","first-page":"760","DOI":"10.4103\/2230-8210.141320","article-title":"Hyponatremia: a practical approach","volume":"18","author":"Sahay","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.ctarc.2026.101233_bib0029","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.21037\/tcr-20-2123","article-title":"The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases","volume":"10","author":"Ren","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101233_bib0030","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s11739-016-1508-5","article-title":"Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department","volume":"12","author":"Castello","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0031","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eprac.2025.04.012","article-title":"Low-dose Tolvaptan for the treatment of syndrome of inappropriate antidiuretic hormone-associated hyponatremia: a systematic review, Meta-analysis, and meta-regression analysis of clinical effectiveness and safety","volume":"31","author":"Lewellyn","year":"2025","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ctarc.2026.101233_bib0032","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300107","article-title":"Severe hyponatremia correction, mortality, and Central pontine myelinolysis","volume":"2","author":"Seethapathy","year":"2023","journal-title":"NEJM. Evid."},{"key":"10.1016\/j.ctarc.2026.101233_bib0033","article-title":"Abstract book of the 21st ECIM Congress","volume":"10","author":"Ejcrim","year":"2023","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(13)70261-7","article-title":"40PD Small cell lung cancer and hyponatremia: interim results from a prospective, observational, global registry","volume":"80","author":"Makin","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.xkme.2019.09.004","article-title":"Equivalent efficacy and decreased rate of overcorrection in patients with syndrome of inappropriate secretion of antidiuretic hormone given very low-dose Tolvaptan","volume":"2","author":"Hanna","year":"2020","journal-title":"Kidney Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0036","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12020-023-03457-w","article-title":"Long-term low-dose tolvaptan efficacy and safety in SIADH","volume":"82","author":"Bondanelli","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.ctarc.2026.101233_bib0037","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eprac.2024.12.019","article-title":"Efficacy and safety of low-dose Tolvaptan (7.5 mg) in the treatment of inpatient hyponatremia: a retrospective study","volume":"31","author":"Llewellyn","year":"2025","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ctarc.2026.101233_bib0038","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/TCRM.S286952","article-title":"Safety profile of Tolvaptan in the treatment of autosomal dominant polycystic kidney disease","volume":"17","author":"Bellos","year":"2021","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.ctarc.2026.101233_bib0039","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMcp2210411","article-title":"The syndrome of inappropriate antidiuresis","volume":"389","author":"Adrogue","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000333301","article-title":"\u00d6sterreichischen und schweizerischen gesellschaften f\u00fcr h\u00e4matologie und onkologie. Basel, 30.09.\u201304.10. 2011","volume":"34","author":"Deutschen","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.ctarc.2026.101233_bib0041","article-title":"A case of hyponatremia due to SIADH treated with tolvaptan, a new selective vasopressin V2-receptor antagonist","volume":"5","author":"Vezzadini","year":"2011","journal-title":"Italian J. Med."},{"key":"10.1016\/j.ctarc.2026.101233_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d1118","article-title":"Investigating hyponatraemia","volume":"342","author":"Wakil","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101233_bib0043","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1055\/s-0031-1286066","article-title":"Praxisnaher Leitfaden zum Vorgehen bei Hyponatri\u00e4mie","volume":"136","author":"Gross","year":"2011","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.ctarc.2026.101233_bib0044","first-page":"53","article-title":"A case in which tolvaptan showed remarkable efficacy for refractory syndrome of inappropriate antidiuretic hormone secretion (SIADH) caused by small cell lung cancer","author":"Tomomatsu","year":"2013","journal-title":"Lung Cancer (Haigan)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(13)70191-0","article-title":"191 Hyponatraemia secondary to SIADH in small cell lung cancer treated with tolvaptan","volume":"79","author":"Pothina","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0046","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1053\/j.ajkd.2013.01.034","article-title":"Role of vaptans in the management of hyponatremia","volume":"62","author":"Lehrich","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ctarc.2026.101233_bib0047","first-page":"2077","article-title":"Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan]","volume":"139","author":"Schnaiter","year":"2014","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.ctarc.2026.101233_bib0048","article-title":"Poster sessions","volume":"10","year":"2015","journal-title":"J. Thoracic Oncology."},{"key":"10.1016\/j.ctarc.2026.101233_bib0049","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11096-014-0039-2","volume":"37","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101233_bib0050","volume":"87","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-5002(15)50157-8","article-title":"163: syndrome of inappropriate antidiuretic hormone (SIADH) secretion in small cell lung cancer: 12 months experience from a cancer unit","volume":"87","author":"Bulusu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101233_bib0052","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12020-016-0936-3","article-title":"SIADH: differential diagnosis and clinical management","volume":"55","author":"Peri","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.ctarc.2026.101233_bib0053","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11845-016-1482-y","volume":"185","year":"2016","journal-title":"Irish J. Med. Sci. (1971)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0054","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00108-017-0321-1","article-title":"Hyponatri\u00e4mie bei einer 58-j\u00e4hrigen patientin mit einem EGFR-positiven pulmonalen Adenokarzinom","volume":"59","author":"Koch","year":"2018","journal-title":"Internist (Berl)"},{"key":"10.1016\/j.ctarc.2026.101233_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.296","article-title":"Successful treatment by tolvaptan of the syndrome of inappropriate antidiuretic hormone secretion that may be associated with chemotherapy-induced tumour lysis in a patient with small-cell lung carcinoma","volume":"6","author":"Miyashita","year":"2018","journal-title":"Respirol. Case Rep."},{"key":"10.1016\/j.ctarc.2026.101233_bib0056","first-page":"58","article-title":"A case of syndrome of inappropriate antidiuretic hormone secretion (SIADH) associated with small cell lung cancer persisting after Mozavaptan administration, successfully treated with Tolvaptan","author":"Kobayashi","year":"2018","journal-title":"Lung Cancer (Haigan)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:39:20Z","timestamp":1780918760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":56,"alternative-id":["S2468294226001449"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101233","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolvaptan for paraneoplastic SIADH in small cell lung cancer: a scoping review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101233"}}